Although the US health reform law may well result in extended health insurance coverage and increase government involvement in healthcare, costs are expected to escalate. In the short-term though, discounts and rebates implemented as part of the reform are expected to result in drop in US sales.
Reforms in the emerging markets concentrate on improving the quality and coverage of healthcare, providing opportunities for pharma, particularly for generics manufacturers. Nevertheless, as healthcare access expands and quality improves, funding pressures increase, leading to the Introduction of cost-containment.
Your key questions answered
* Evaluate key factors driving healthcare expenditure as well as measures implemented by governments strategies implemented to contain further growth.
* Gain insight into the impact of healthcare reforms in the developed and emerging markets and their impact on pharma.
* Assess pharma's responses to the increasingly tough regulatory and reimbursement environment.
Strategic scoping and focus
Key growth drivers and resistors facing healthcare payers and pharma
Pricing and reimbursement
Upcoming related reports
Healthcare expenditure is growing fast
There are several factors driving up healthcare expenditure across the markets analyzed:
The proportion of public contribution to healthcare is greater in the developed as compared to the emerging markets
However, despite improving economies, the emerging markets like the developed markets, are under pressure to contain costs, leading to implementation of strategies such as price cuts that are impacting pharma companies operating in such markets.
Copyright©2010 PR Newswire.
All rights reserved